[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 40 of about 40
1. Riganti C, Doublier S, Aldieri E, Orecchia S, Betta PG, Gazzano E, Ghigo D, Bosia A: Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha. Eur Respir J; 2008 Aug;32(2):443-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
  • Human malignant mesothelioma (HMM), which is strongly related to asbestos exposure, exhibits high resistance to many anticancer drugs.
  • Asbestos fibre deposition in the lung may cause hypoxia and iron chelation at the fibre surface.
  • The present study aimed to assess whether asbestos may play a role in the induction of doxorubicin resistance in HMM cells through the activation of HIF-1alpha and an increased expression of Pgp.
  • After 24-h incubation with crocidolite asbestos or with the iron chelator dexrazoxane, or under hypoxia, HMM cells were tested for HIF-1alpha activation, Pgp expression, accumulation of doxorubicin and sensitivity to its toxic effect.
  • Crocidolite, dexrazoxane and hypoxia induce doxorubicin resistance in human malignant mesothelioma cells by increasing hypoxia-inducible factor-1alpha activity, through an iron-sensitive mechanism.
  • [MeSH-major] Asbestos / toxicity. Drug Resistance, Neoplasm. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Anoxia. Antineoplastic Agents / pharmacology. Asbestos, Crocidolite / pharmacology. Cell Line, Tumor. Doxorubicin / pharmacology. Humans. Iron / metabolism. Lung / pathology. P-Glycoprotein / metabolism. Razoxane / pharmacology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385176.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / P-Glycoprotein; 12001-28-4 / Asbestos, Crocidolite; 1332-21-4 / Asbestos; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin; E1UOL152H7 / Iron
  •  go-up   go-down


2. Munkholm-Larsen S, Cao CQ, Yan TD: Malignant peritoneal mesothelioma. World J Gastrointest Surg; 2009 Nov 30;1(1):38-48
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • Malignant mesothelioma is a highly aggressive neoplasm.
  • The incidence of malignant mesothelioma is increasing worldwide.
  • Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas.
  • Association of asbestos exposure with DMPM has been observed, especially in males.
  • This remarkable improvement in survival has prompted new search into the medical science related to DMPM, a disease previously ignored as uninteresting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160794.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999110
  • [Keywords] NOTNLM ; Asbestos / Cisplatin / Cytoreductive surgery / Doxorubicin / Intraperitoneal chemotherapy / Mesothelin / Pemetrexed / Peritoneal mesothelioma / Peritonectomy
  •  go-up   go-down


3. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


Advertisement
4. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • RESULTS: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM.
  • CONCLUSIONS: Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor.
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


5. Luo SQ, Mu SH, Wang JT, Zhang Y, Wen QB, Cai SP: [A study on risk of malignant neoplasm and environmental exposure to crocidolite]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Jan;36(1):105-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A study on risk of malignant neoplasm and environmental exposure to crocidolite].
  • OBJECTIVE: To explore the risk of developing malignant neoplasm in a cohort with the history of environmental exposure to crocidolite asbestos.
  • The deaths from and the RR of asbestos-related malignant neoplasms were studied.
  • The crude mortality from lung cancer (56 deaths) was 650.5 per 10(6) person-years,there is no significance between the two groups (RR=1.434; 95%CI: 0.968-2.486).
  • The difference in mortality from gastrointestinal cancer between the two groups is not significant, whereas the risk of man intestinal cancer in the observation is significant (RR=3.71; 95%CI: 1.077-13.270).
  • The risk of man intestinal cancer in the town awaits additional studies.
  • [MeSH-major] Asbestos, Crocidolite / adverse effects. Environmental Exposure / adverse effects. Lung Neoplasms / epidemiology. Mesothelioma / epidemiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702795.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 12001-28-4 / Asbestos, Crocidolite
  •  go-up   go-down


6. Nolan RP, Ross M, Nord GL, Axten CW, Osleeb JP, Domnin SG, Price B, Wilson R: Risk assessment for asbestos-related cancer from the 9/11 attack on the World Trade Center. J Occup Environ Med; 2005 Aug;47(8):817-25
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk assessment for asbestos-related cancer from the 9/11 attack on the World Trade Center.
  • OBJECTIVE: We sought to estimate the lifetime risk of asbestos-related cancer for residents of Lower Manhattan attributable to asbestos released into the air by the 9/11 attack on New York City's World Trade Center (WTC).
  • Cancer risk was assessed using an asbestos risk model that differentiates asbestos fiber-types and the US Environmental Protection Agency's model that does not differentiate fiber-types and combines mesothelioma and lung cancer risks.
  • RESULTS: The upper limit for the expected number of asbestos-related cancers is less than one case over the lifetime of the population for the risk model that is specific for fiber-types and 12 asbestos-related cancers with the US Environmental Protection Agency's model.
  • CONCLUSIONS: The cancer risk associated with asbestos exposures for residents of Lower Manhattan resulting from the collapse of the WTC is negligible.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093931.001).
  • [ISSN] 1076-2752
  • [Journal-full-title] Journal of occupational and environmental medicine
  • [ISO-abbreviation] J. Occup. Environ. Med.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Dust; 1332-21-4 / Asbestos
  •  go-up   go-down


7. Berman DW, Crump KS: A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type. Crit Rev Toxicol; 2008;38 Suppl 1:49-73
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A meta-analysis of asbestos-related cancer risk that addresses fiber size and mineral type.
  • Quantitative estimates of the risk of lung cancer or mesothelioma in humans from asbestos exposure made by the U.S.
  • Environmental Protection Agency (EPA) make use of estimates of potency factors based on phase-contrast microscopy (PCM) and obtained from cohorts exposed to asbestos in different occupational environments.
  • Environmental Protection Agency (EPA) models for asbestos-related lung cancer and mesothelioma are expanded to allow the potency of fibers to depend upon their mineralogical types and sizes.
  • These category-specific potencies are estimated in a meta-analysis that fits the expanded models to potencies for lung cancer (KL's) or mesothelioma (KM's) based on PCM that were calculated for multiple epidemiological studies in our previous paper (Berman and Crump, 2008).
  • The fraction of total asbestos exposure in a given environment respectively represented by chrysotile and amphibole asbestos is also estimated from information in the literature for that environment.
  • Each such metric defined by width was composed of four categories of fibers: chrysotile or amphibole asbestos with lengths between 5 microm and 10 microm or longer than 10 microm.
  • Using these metrics three parameters were estimated for lung cancer and, separately, for mesothelioma: KLA, the potency of longer (length > 10 microm) amphibole fibers; rpc, the potency of pure chrysotile (uncontaminated by amphibole) relative to amphibole asbestos; and rps, the potency of shorter fibers (5 microm < length < 10 microm) relative to longer fibers.
  • For mesothelioma, the hypothesis that chrysotile and amphibole asbestos are equally potent (rpc = 1) was strongly rejected by every metric and the hypothesis that (pure) chrysotile is nonpotent for mesothelioma was not rejected by any metric.
  • Best estimates for the relative potency of chrysotile ranged from zero to about 1/200th that of amphibole asbestos (depending on metric).
  • For lung cancer, the hypothesis that chrysotile and amphibole asbestos are equally potent (rpc = 1) was rejected (p < or = .05) by the two metrics based on thin fibers (length < 0.4 microm and < 0.2 microm) but not by the metrics based on thicker fibers.
  • The "all widths" and widths < 0.4 microm metrics provide the best fits to both the lung cancer and mesothelioma data over the other metrics evaluated, although the improvements are only marginal for lung cancer.
  • That these two metrics provide equivalent (for mesothelioma) and nearly equivalent (for lung cancer) fits to the data suggests that the available data sets may not be sufficiently rich (in variation of exposure characteristics) to fully evaluate the effects of fiber width on potency.
  • Compared to the metric with widths > 0.2 microm with both rps and rpc fixed at 1 (which is nominally equivalent to the traditional PCM metric), the "all widths" and widths < 0.4 microm metrics provide substantially better fits for both lung cancer and, especially, mesothelioma.
  • Expansion of these metrics to include a category for fibers with lengths < 5 microm did not find any consistent evidence for any potency of these shortest fibers for either lung cancer or mesothelioma.
  • Unresolved in particular is the discrepancy in potency factors for lung cancer from Quebec chrysotile miners and workers at the Charleston, SC, textile mill, which mainly processed chrysotile from Quebec.
  • [MeSH-major] Asbestos, Amphibole / toxicity. Asbestos, Serpentine / toxicity. Carcinogens, Environmental / toxicity. Lung Neoplasms / chemically induced. Mesothelioma / chemically induced

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18686078.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Asbestos, Serpentine; 0 / Carcinogens, Environmental
  •  go-up   go-down


8. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res; 2009 Jun 1;69(11):4598-604
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
  • Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase in the next decades.
  • Female gender was identified as a positive prognostic factor among other clinical and biological prognostic markers for malignant mesothelioma, yet a role of estrogen receptors (ERs) has not been studied.
  • Our goal was to investigate ERs expression in malignant mesothelioma and to assess whether their expression correlates with prognosis.
  • Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival.
  • Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation.
  • Our data support the notion that ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression and to therapeutic response of malignant mesothelioma patients.


9. Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M, Ferrante D, Guarrera S, Betta GP, Mirabelli D, Matullo G, Magnani C: Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res; 2006 Jul 25;599(1-2):124-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study.
  • This paper describes the results of a case-control epidemiological study designed to determine the genotypes of four of these genes in persons exposed to a single genotoxic factor, i.e. asbestos, who had or had not developed malignant mesothelioma (MM).
  • Our working hypothesis was that an imperfect DNA repair, as revealed by subtle polymorphic variants, could reduce protection against the chronic DNA insult provoked by asbestos and eventually result in mutagenesis and cancer.
  • XRCC1-R399Q-NCBI SNP, XRCC1-R194W, XRCC3-T241M, XRCC3-IVS6-14, XPD-K751Q, XPD-D312N, OGG1-S326C) were investigated in 81 patients and 110 age and sex-matched controls, all residents at Casale Monferrato, a Piedmontese town highly exposed to asbestos pollution.
  • This is the first report of an association between polymorphisms in DNA repair genes and asbestos-associated MM.
  • [MeSH-major] Asbestos / adverse effects. DNA Repair / genetics. Mesothelioma / etiology. Mesothelioma / genetics. Pleural Neoplasms / etiology. Pleural Neoplasms / genetics. Polymorphism, Genetic
  • [MeSH-minor] Aged. Base Sequence. Case-Control Studies. DNA Glycosylases / genetics. DNA Primers / genetics. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Female. Gene Frequency. Haplotypes. Humans. Italy. Male. Middle Aged. Risk Factors. Xeroderma Pigmentosum Group D Protein / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564556.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3; 1332-21-4 / Asbestos; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


10. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • Asbestos has been widely used in industry.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology


11. Yasuda M, Hanagiri T, Shigematsu Y, Onitsuka T, Kuroda K, Baba T, Mizukami M, Ichiki Y, Uramoto H, Takenoyama M, Yasumoto K: Identification of a tumour associated antigen in lung cancer patients with asbestos exposure. Anticancer Res; 2010 Jul;30(7):2631-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a tumour associated antigen in lung cancer patients with asbestos exposure.
  • BACKGROUND: This study analysed the humoral immune response in asbestos exposed lung cancer patients to identify new surrogate markers of the carcinogenic risk in populations exposed to asbestos.
  • METHODS AND RESULTS: A serological analysis identified five distinct antigens reactive with IgG derived from a lung cancer patient with high asbestos exposure.
  • In one of the isolated antigens, quantitative RT-PCR indicated that annexin A2 (AnxA2) was overexpressed in lung cancer tissues and normal lung from patients with high asbestos exposure.
  • Antibody against AnxA2 was detected in 9/15 (60%) of lung cancer patients with high asbestos exposure; however, in only 1/12 (8%) of lung cancer patients with low asbestos exposure.
  • AnxA2 was also overexpressed in malignant mesothelioma cells, and the antibody was also positive in 8/15 (53%) of patients with malignant mesothelioma.
  • CONCLUSION: The antibody titer against AnxA2 may be a potentially useful new diagnostic surrogate marker for asbestos-related lung cancer and malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Asbestos / poisoning. Lung Neoplasms / etiology. Lung Neoplasms / immunology
  • [MeSH-minor] Aged. Aged, 80 and over. Annexin A2 / biosynthesis. Annexin A2 / immunology. Antibodies, Neoplasm / immunology. Enzyme-Linked Immunosorbent Assay. Humans. Immunity, Humoral / immunology. Immunoglobulin G / immunology. Interleukin-6 / blood. Interleukin-6 / immunology. Male. Mesothelioma / etiology. Mesothelioma / immunology. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20682992.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / ANXA2 protein, human; 0 / Annexin A2; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Immunoglobulin G; 0 / Interleukin-6; 1332-21-4 / Asbestos
  •  go-up   go-down


12. Brauer C, Baandrup U, Jacobsen P, Krasnik M, Olsen JH, Pedersen JH, Rasmussen TR, Schlünssen V, Sherson D, Svolgaard B, Sørensen JB, Omland O: [Screening for asbestos-related conditions]. Ugeskr Laeger; 2009 Feb 2;171(6):433-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Screening for asbestos-related conditions].
  • Screening programs for early detection of asbestos-related cancer have been considered.
  • Conventional X-ray, computed tomography of the thorax, and the biomarkers osteopontin and mesothelin have been critically reviewed in the literature, together with survival data from screening programs in asbestos-exposed populations.
  • Data do not currently support implementation of screening programs for asbestos-exposed persons in Denmark.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / etiology. Mesothelioma / etiology. Occupational Diseases / etiology


13. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer; 2008 Aug;61(2):235-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
  • Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker.
  • The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure.
  • Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed.
  • Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median=6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22).
  • High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure.
  • Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Keratins / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis. Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Asbestos / adverse effects. Case-Control Studies. Child. Child, Preschool. Female. GPI-Linked Proteins. Humans. Infant. Keratin-19. Male. Occupational Exposure / adverse effects. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281122.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Keratin-19; 0 / Membrane Glycoproteins; 0 / NBR1 protein, human; 0 / Proteins; 0 / antigen CYFRA21.1; 0 / mesothelin; 1332-21-4 / Asbestos; 68238-35-7 / Keratins
  •  go-up   go-down


14. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med; 2006 May 15;173(10):1155-60
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
  • BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue.
  • Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.
  • METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.
  • [MeSH-major] Asbestosis / pathology. Membrane Glycoproteins / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology. Sialoglycoproteins / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Disease Progression. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Neoplasm Staging. Osteopontin. Prognosis. Prospective Studies. Sensitivity and Specificity. Solubility. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456138.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


15. Bonde JP: [Occupational medicine--origins and perspectives]. Ugeskr Laeger; 2009 Feb 9;171(7):529-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Technological innovation and preventive measures have had a major impact on the occurrence of occupational disease in Denmark over the past 50 years, although some diseases such as asbestos-related cancer are still being diagnosed.

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210938.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


16. Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J: Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol; 2009 Jun;2(2):190-206
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
  • Malignant mesothelioma (MM) is an aggressive neoplasm of serosal cavities, which is resistant to conventional therapy, with patient survival from presentation of <12 months.
  • Although the main risk factor is asbestos exposure, other factors, Simian virus 40 infection and inheritance of susceptibility genes, likely play a role.
  • Asbestos-related carcinogenic process is primarily based on the interaction between susceptibility (genetic and acquired) and exposure to carcinogenic environmental agents.
  • Asbestos-induced carcinogenesis includes generation of reactive oxygen species, which induce DNA strand breaks and oxidant-induced base modifications to DNA.
  • Several programs have been used to screen asbestos-exposed individuals for lung and pleural disease.
  • [MeSH-minor] Asbestos / toxicity. Carcinogens / toxicity. DNA Damage. Humans. Mitogen-Activated Protein Kinases / metabolism. NF-kappa B / metabolism. Simian virus 40 / physiology. Transcription Factor AP-1 / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021458.001).
  • [ISSN] 1874-4702
  • [Journal-full-title] Current molecular pharmacology
  • [ISO-abbreviation] Curr Mol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Carcinogens; 0 / NF-kappa B; 0 / Transcription Factor AP-1; 1332-21-4 / Asbestos; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Number-of-references] 180
  •  go-up   go-down


17. Brunner WM, Williams AN, Bender AP: Investigation of exposures to commercial asbestos in northeastern Minnesota iron miners who developed mesothelioma. Regul Toxicol Pharmacol; 2008 Oct;52(1 Suppl):S116-20
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of exposures to commercial asbestos in northeastern Minnesota iron miners who developed mesothelioma.
  • A 70% excess of mesothelioma, an asbestos-related cancer, has been reported among men in northeastern Minnesota, where iron mining has been the major industry.
  • The Minnesota Department of Health has studied iron miners who developed mesothelioma to identify possible sources of asbestos exposure.
  • The job histories of the cases were examined to determine if any of their jobs could have involved exposure to commercial asbestos.
  • Of the 15 for whom adequate work histories were available, 14 had identifiable sources of exposure to commercial asbestos in jobs held both inside and outside of the mining industry.
  • The time between employment in these asbestos-exposed occupations and the diagnosis of mesothelioma is consistent with the 20 or more year latency period that has been observed in other studies of this cancer.
  • [MeSH-major] Air Pollutants, Occupational / adverse effects. Asbestos / adverse effects. Asbestosis / etiology. Mesothelioma / etiology. Mining. Peritoneal Neoplasms / etiology. Pleural Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988773.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 1332-21-4 / Asbestos
  •  go-up   go-down


18. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G: MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol; 2010 Mar;42(3):312-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
  • Human malignant mesothelioma is an asbestos-related cancer, with poor prognosis and low median survival.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502386.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


19. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens; 2009 Jul;74(1):1-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
  • Whether the immune system can recognize malignant and premalignant cells and eliminate them to prevent the development of cancer is still a matter of open debate, but in our view, the balance of evidence favours this concept.
  • Nonetheless, the International Agency for Research on Cancer has now predicted that cancer will overtake heart disease as the leading cause of death worldwide by 2010, showing that this protective mechanism often fails.
  • Malignant mesothelioma has traditionally been considered a relatively non-immunogenic cancer.
  • Over recent years, there has been increasing interest in the possibility of combining immunotherapy with chemotherapy in the fight against cancer.
  • Here, we discuss the rationale behind combining these two, long considered antagonistic, treatment options in the context of malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunosuppression. Mesothelioma / therapy. Neoplasms, Mesothelial / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422663.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cytokines
  • [Number-of-references] 93
  •  go-up   go-down


20. Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W: Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2008 Jul;34(1):204-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma is a mainly asbestos-related neoplasm that occurs with increasing frequency and is associated with a poor prognosis.
  • We therefore analysed our experience with extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
  • METHODS: We retrospectively reviewed our institutional experience with all consecutive patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma from 1994 to 2005.
  • CONCLUSION: Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407510.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Witherby SM, Butnor KJ, Grunberg SM: Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer; 2007 Sep;57(3):410-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma following thoracic radiotherapy for lung cancer.
  • As the number of long-term cancer survivors increases, secondary malignancies are becoming a greater clinical issue.
  • Although some of these malignancies may be related to common environmental exposures, a significant number are considered to be therapy-related.
  • Pleural malignant mesothelioma is a neoplasm that may be related to asbestos exposure or radiation exposure.
  • Previous reports of pleural mesothelioma as a second malignancy have tended to follow radiotherapy for extra-thoracic malignancies such as Hodgkin's disease, breast cancer and Wilms' tumor.
  • We report the case of a 66-year-old woman with no prior asbestos exposure who developed pleural mesothelioma 17 years after pneumonectomy and adjuvant radiation therapy for non-small cell lung cancer.


22. Røe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S: Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer; 2010 Jan;67(1):57-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets.
  • Malignant pleural mesothelioma is an asbestos-related multi-resistant tumour with increasing incidence worldwide.
  • Gene expression features found in other resistant cancer types related to DNA repair and replication are shared by mesothelioma and could represent general features of tumour resistance.
  • [MeSH-major] Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Mesothelioma / genetics. Pleural Neoplasms / genetics. Radiation Tolerance / genetics
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Asbestos / toxicity. Genome-Wide Association Study. Humans


23. Gun R, Pratt NL, Roder DM, Ryan P: Asbestos-related cancers in refinery workers in the Australian petroleum industry. Arch Environ Occup Health; 2006 Jan-Feb;61(1):11-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related cancers in refinery workers in the Australian petroleum industry.
  • In this study of the incidence of asbestos-related cancer in the Australian petroleum industry, the authors traced a cohort of 16,543 petroleum industry workers for a total of 226,989 person-years.
  • The incidence of lung cancer was significantly lower than that in the general male population.
  • Lung cancer incidence was higher in maintenance workers than in nonmaintenance workers, but the excess was not statistically significant, as it was based on small numbers with wide confidence intervals.
  • Lung cancer rates in refinery workers did not increase with duration of employment; however, they did tend to be higher in workers hired in earlier decades.
  • Excess mesothelioma incidence in refinery workers is confirmed, but it is likely that there are few if any asbestos-related lung cancers.
  • [MeSH-major] Asbestos / adverse effects. Industry. Lung Neoplasms / epidemiology. Mesothelioma / epidemiology. Petroleum

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503616.001).
  • [ISSN] 1933-8244
  • [Journal-full-title] Archives of environmental & occupational health
  • [ISO-abbreviation] Arch Environ Occup Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Petroleum; 1332-21-4 / Asbestos
  •  go-up   go-down


24. Bianchi C, Bianchi T: Susceptibility and resistance in the genesis of asbestos-related mesothelioma. Indian J Occup Environ Med; 2008 Aug;12(2):57-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility and resistance in the genesis of asbestos-related mesothelioma.
  • Asbestos is the principal agent in the etiology of malignant mesothelioma.
  • However, a small proportion of people exposed to asbestos develop mesothelioma.
  • A genetic susceptibility is suggested by the occurrence of more mesothelioma cases among blood-related members of a single family.
  • This indicates a particular vulnerability to cancer in people with mesothelioma.
  • Not rarely, very old persons heavily exposed to asbestos remain free from asbestos-related cancer, a fact indicating an absolute resistance to the oncogenic effects of asbestos.
  • A relative resistance may be recognized in people severely exposed to asbestos who develop mesothelioma only after 60 years or more since the onset of the exposure.
  • The natural history of mesothelioma shows that a resistance to the oncogenic effects of asbestos does exist.
  • To strengthen the defence mechanisms may represent a way for preventing mesothelioma among people exposed to asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 2007 May;50(5):357-69 [17407142.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1432-8 [17315168.001]
  • [Cites] Lancet. 2007 Mar 10;369(9564):844-9 [17350453.001]
  • [Cites] Respir Med. 2007 Mar;101(3):503-9 [16919927.001]
  • [Cites] Chest. 2007 Feb;131(2):376-82 [17296636.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):314-5 [17184695.001]
  • [Cites] Thorax. 2006 Oct;61(10):916-7 [17008483.001]
  • [Cites] Mutat Res. 2006 Jul 25;599(1-2):124-34 [16564556.001]
  • [Cites] Med Lav. 2005 Jul-Aug;96(4):287-303 [16457426.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):36-44 [15993904.001]
  • [Cites] Chest. 1993 Apr;103(4):1268-9 [8131480.001]
  • [Cites] Ind Health. 2004 Apr;42(2):235-9 [15128174.001]
  • [Cites] Transplantation. 2003 Nov 27;76(10):1448-51 [14657684.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):63-8 [14512189.001]
  • [Cites] Ann Occup Hyg. 2003 Aug;47(6):485-92 [12890657.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):1-9 [12004841.001]
  • [Cites] Ind Health. 2001 Apr;39(2):161-7 [11341546.001]
  • [Cites] Ind Health. 2000 Jul;38(3):301-8 [10943078.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S87-90 [10582147.001]
  • [Cites] Mutat Res. 2008 Mar-Apr;658(3):162-71 [17904414.001]
  • [Cites] Int J Occup Environ Health. 2007 Oct-Dec;13(4):398-403 [18085053.001]
  • [Cites] Med Lav. 2007 Sep-Oct;98(5):374-80 [17907531.001]
  • [Cites] Bull Cancer. 2007 Jul;94(7):705-10 [17723954.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):407-9 [17400330.001]
  • [Cites] Ind Health. 2007 Jun;45(3):379-87 [17634686.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):19-22 [17455866.001]
  • (PMID = 20040979.001).
  • [ISSN] 1998-3670
  • [Journal-full-title] Indian journal of occupational and environmental medicine
  • [ISO-abbreviation] Indian J Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2796755
  • [Keywords] NOTNLM ; Asbestos / familial cancer / host factors / immune impairment / mesothelioma / resistance / susceptibility
  •  go-up   go-down


25. Bolognesi C, Martini F, Tognon M, Filiberti R, Neri M, Perrone E, Landini E, Canessa PA, Ivaldi GP, Betta P, Mutti L, Puntoni R: A molecular epidemiology case control study on pleural malignant mesothelioma. Cancer Epidemiol Biomarkers Prev; 2005 Jul;14(7):1741-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A molecular epidemiology case control study on pleural malignant mesothelioma.
  • Pleural malignant mesothelioma is an uncommon neoplasm usually associated with asbestos exposure.
  • The increasing incidence of malignant mesothelioma cases involving individuals with low levels of asbestos exposure suggests a complex carcinogenetic process with the involvement of other cofactors.
  • Cytogenetic studies revealed the complexity of the genetic changes involved in this neoplasm reflecting the accumulation of genomic damage.
  • A biomonitoring study was carried out to evaluate the micronuclei frequency in PBLs of patients with pleural malignant mesothelioma with respect to lung cancer, healthy, and risk controls as a marker of cancer susceptibility in correlation with the presence of SV40.
  • A significant increased micronuclei frequency was observed in patients with malignant mesothelioma in comparison with all the other groups, the mean micronuclei frequency was double in patients with malignant mesothelioma compared with healthy controls, risk controls, and patients with lung adenocarcinoma (median 11.4 binucleated cells with micronuclei/1,000 binucleated cells versus 6.2, 6.1, and 5.1, respectively).
  • Our data indicate that human T lymphocyte samples carry DNA sequences coding for SV40 large T antigen at low prevalence, both in cancer cases and controls.
  • Evidence of cytogenetic damage revealed as micronuclei frequency in mesothelioma cancer patients could be related to exogenous and endogenous cofactors besides asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Lung Neoplasms / genetics. Mesothelioma / etiology. Molecular Epidemiology. Pleural Neoplasms / etiology. Smoking / adverse effects

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16030111.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


26. Moore S, Darlison L, Tod AM: Living with mesothelioma. A literature review. Eur J Cancer Care (Engl); 2010 Jul;19(4):458-68
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is an asbestos-related cancer that affects mainly the pleura.
  • The findings suggest the impact of mesothelioma is multidimensional on: physical symptoms (especially pain, breathlessness, fatigue, cough, sleep disturbance, appetite loss and sweating), emotional functioning (anxiety, depression, fear and isolation), social consequences (changes in roles and relationships) and interventions (the necessity of frequent anti-cancer treatments and admissions for symptom control).

  • MedlinePlus Health Information. consumer health - Caregivers.
  • MedlinePlus Health Information. consumer health - Family Issues.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19832887.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


27. Burdett G, Bard D: Exposure of UK industrial plumbers to asbestos, Part I: Monitoring of exposure using personal passive samplers. Ann Occup Hyg; 2007 Mar;51(2):121-30
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure of UK industrial plumbers to asbestos, Part I: Monitoring of exposure using personal passive samplers.
  • Epidemiological data suggest that there has been and may continue to be a significant risk to maintenance workers, who through their work may disturb asbestos-containing materials (ACM).
  • The asbestos exposure of industrial plumbers was measured using personal passive samplers developed at the Health and Safety Laboratory (HSL).
  • The light-weight samplers, which collect particles by electrostatic attraction, are simple to use and do not require prior knowledge that asbestos is to be disturbed as does conventional sampling.
  • The strategy was found to be a reasonably efficient and cost-effective way to obtain data on maintenance worker's exposure to asbestos.
  • The results of the TEM analysis of the passive samplers showed that the percentage of workers exposed to >5 microm long asbestos fibres was 62% in Round 1 and 58% in Round 2.
  • For phase contrast microscopy equivalent (PCME) asbestos fibres, the values were 46 and 29%, respectively.
  • The three samples with the highest numbers of fibres were followed up and were associated with plumbers working in areas which had supposedly been stripped of asbestos just prior to their starting work, suggesting that poor removal, clean-up and clearance practice presents a significant part of the risk to plumbers.
  • This gave an average exposure to regulated PCME fibres of 0.009 f ml-1 for amphibole asbestos and 0.049 f ml-1 for chrysotile.
  • If representative, the estimated lifetime risk of death from an asbestos related cancer for an exposure from age 20 for 40 years would be 68 per 100,000, which equates to an annual risk of death of the order of 10 per million.
  • [MeSH-major] Air Pollutants, Occupational / toxicity. Asbestos / toxicity. Carcinogens, Environmental / toxicity. Environmental Monitoring / instrumentation. Occupational Exposure / adverse effects
  • [MeSH-minor] Asbestos, Amphibole / analysis. Asbestos, Amphibole / toxicity. Asbestos, Serpentine / analysis. Asbestos, Serpentine / toxicity. Dust / analysis. Equipment Design. Great Britain. Hazardous Substances / analysis. Hazardous Substances / toxicity. Humans. Inhalation Exposure / adverse effects. Microscopy, Electron / methods. Microscopy, Phase-Contrast / methods. Particle Size. Population Surveillance / methods. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17189281.001).
  • [ISSN] 0003-4878
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Asbestos, Amphibole; 0 / Asbestos, Serpentine; 0 / Carcinogens, Environmental; 0 / Dust; 0 / Hazardous Substances; 1332-21-4 / Asbestos
  •  go-up   go-down


28. Kothmaier H, Quehenberger F, Halbwedl I, Morbini P, Demirag F, Zeren H, Comin CE, Murer B, Cagle PT, Attanoos R, Gibbs AR, Galateau-Salle F, Popper HH: EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors. Thorax; 2008 Apr;63(4):345-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related tumour difficult to detect early and treat effectively.
  • Asbestos causes genetic modifications and cell signalling events that favour the resistance of MPM to apoptosis and chemotherapy.
  • Antiapoptosis was upregulated in STS by signal transducer and activator of transcription 1 (STAT1)-survivin and related molecules, but not in LTS.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / pathology. Neoplasm Proteins / metabolism. Pleural Neoplasms / pathology. Receptor, Epidermal Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086752.001).
  • [ISSN] 1468-3296
  • [Journal-full-title] Thorax
  • [ISO-abbreviation] Thorax
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


29. Watanabe Y, Kojima T, Kagawa S, Uno F, Hashimoto Y, Kyo S, Mizuguchi H, Tanaka N, Kawamura H, Ichimaru D, Urata Y, Fujiwara T: A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy. Oncogene; 2010 Feb 25;29(8):1145-54
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy.
  • Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that is related to asbestos exposure.
  • Our results suggest that intrathoracic dual virotherapy with telomerase-specific oncolytic adenovirus in combination with heparanase-expressing adenovirus may be efficacious in the prevention and treatment of pleural dissemination of human malignant mesothelioma.
  • [MeSH-minor] Animals. Cell Line, Tumor. Combined Modality Therapy. Gene Expression Regulation, Neoplastic. Gene Transfer Techniques. Humans. Lung Neoplasms / chemically induced. Lung Neoplasms / therapy. Mice. Mice, Nude. Neoplasm Transplantation. Protein Biosynthesis. Virus Replication. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935710.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


30. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J: Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg; 2008 Jan;85(1):265-72; discussion 272
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
  • BACKGROUND: Soluble mesothelin-related peptide (SMRP) is a potential marker for malignant pleural mesothelioma (MPM), which may be useful for screening high-risk asbestos-exposed individuals.
  • METHODS: We evaluated SMRP in serum from MPM patients (n = 90), lung cancer patients (n = 170), age and tobacco-matched asbestos-exposed individuals (n = 66), and in MPM pleural effusions (n = 45), benign effusions (n = 30), and non-MPM effusions (n = 20) using the MesoMark enzyme-linked immunosorbent assay kit (Fujirebio Diagnostics, Malvern, PA).
  • RESULTS: Mean serum SMRP levels were higher in MPM compared with lung cancer (5.67 +/- 0.82 nM [mean +/- standard error of the mean vs 1.99 +/- 0.43 nM, p < 0.001), and stage I MPM SMRP levels (n = 12; 2.09 +/- 0.41 nM) were significantly higher than those in asbestos-exposed individuals (0.99 +/- 0.09 nM, p = 0.02, respectively).
  • The area under the ROC curve for serum SMRP was 0.81 for differentiating MPM and asbestos-exposed individuals; cutoff = 1.9 nM (sensitivity = 60%, specificity = 89%).
  • CONCLUSIONS: These data support SMRP as a promising marker for MPM in both serum and pleural effusion fluid, and justify prospective screening studies of SMRP in combination with other markers for screening of asbestos-exposed cohorts.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Effusion, Malignant / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Area Under Curve. Asbestosis / blood. Asbestosis / complications. Asbestosis / mortality. Asbestosis / pathology. Case-Control Studies. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prognosis. ROC Curve. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18154821.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


31. Catalano A, Lazzarini R, Di Nuzzo S, Orciari S, Procopio A: The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells. Cancer Res; 2009 Feb 15;69(4):1485-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The plexin-A1 receptor activates vascular endothelial growth factor-receptor 2 and nuclear factor-kappaB to mediate survival and anchorage-independent growth of malignant mesothelioma cells.
  • Here, we show that in asbestos-related malignant pleural mesothelioma (MPM), Semaphorin-6D (Sema6D) and its receptor plexin-A1 are frequently expressed and trigger a prosurvival program that promotes anchorage-independent growth of MPM cells.
  • Expression of Sema6D and plexin-A1 is induced by asbestos fibers and overexpression of plexin-A1 in nonmalignant mesothelial cells inhibits cell death after asbestos exposure.
  • This work identifies a new biological function of semaphorins in cancer cells and suggests the involvement of an undescribed survival pathway during MPM tumorigenesis.
  • [MeSH-minor] Apoptosis. Cell Adhesion. Cell Division. Cell Survival. Colony-Forming Units Assay. Genes, Reporter. Humans. Immunoblotting. Phenotype. Plasmids. RNA, Neoplasm / genetics. Signal Transduction. Transfection. Vascular Endothelial Growth Factor Receptor-1 / physiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176370.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Nerve Tissue Proteins; 0 / PLXNA1 protein, human; 0 / RNA, Neoplasm; 0 / Receptors, Cell Surface; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


32. Nakataki E, Yano S, Matsumori Y, Goto H, Kakiuchi S, Muguruma H, Bando Y, Uehara H, Hamada H, Kito K, Yokoyama A, Sone S: Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci; 2006 Mar;97(3):183-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
  • Malignant pleural mesothelioma (MPM) is closely related to exposure to asbestos, and a rapid increase in the number of MPM patients in Japan is estimated in the years 2010-2050.
  • EHMES-10 cells overexpressed vascular endothelial growth factor (VEGF), a molecule responsible for malignant effusions, and its receptor.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Humans. Immunohistochemistry. Male. Mice. Mice, SCID. Neoplasm Transplantation. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - EHMES-10 (CVCL_M208) .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16542214.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Vascular Endothelial Growth Factor A; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Ameille J, Brochard P, Letourneux M, Paris C, Pairon JC: [Asbestos-related cancer risk in the presence of asbestosis or pleural plaques]. Rev Mal Respir; 2009 Apr;26(4):413-21; quiz 480, 483
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos-related cancer risk in the presence of asbestosis or pleural plaques].
  • [Transliterated title] Risque de cancer lié à l'amiante en présence d'asbestose ou de plaques pleurales.
  • INTRODUCTION: The relationships between benign asbestos-related diseases (asbestosis and pleural plaques) and thoracic cancers are still debated.
  • STATE OF THE ART: Published studies show that there is a significant relationship between occupational exposure to asbestos and lung cancer risk, even in the absence of abnormalities consistent with asbestos exposure on postero-anterior chest x-ray.
  • In subjects with occupational exposure to asbestos, an increased risk of lung cancer and pleural mesothelioma is observed in subjects with pleural plaques on chest x-ray, in comparison with the general population.
  • In exposed subjects with similar cumulative exposure to asbestos, it is not demonstrated that pleural plaques are associated with an increased risk of lung cancer or pleural mesothelioma.
  • Their results must be confirmed by additional studies including a rigorous evaluation of the cumulative exposure to asbestos and chest CT-scans.
  • CONCLUSION: In the present state of knowledge, isolated pleural plaques do not justify specific medical surveillance, as compared to that required by the mere estimated cumulative exposure to asbestos.


34. Ray M, Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest; 2009 Sep;136(3):888-896
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: an update on biomarkers and treatment.
  • Although the insulating properties of asbestos have been known for millennia, the link between asbestos exposure and mesothelioma was not recognized until 1960, when it was first described in South African asbestos miners.
  • The incidence of mesothelioma parallels asbestos usage with a latency of 20 to 40+ years; thus, patient numbers are declining in the United States but rising in the developing world.
  • Newly described biomarkers, including soluble mesothelin-related peptide, megakaryocyte potentiation factor, and osteopontin, may predict which asbestos-exposed individuals will develop mesothelioma, and may prove useful in assessing response to treatment.
  • This combination improves response, survival, time to progression, pulmonary function, and disease-related symptoms.
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis


35. Wilson R, McConnell EE, Ross M, Axten CW, Nolan RP: Risk assessment due to environmental exposures to fibrous particulates associated with taconite ore. Regul Toxicol Pharmacol; 2008 Oct;52(1 Suppl):S232-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the early 1970s, it became a concern that exposure to the mineral fibers associated taconite ore processed in Silver Bay, Minnesota would cause asbestos-related disease including gastrointestinal cancer.
  • To further our understanding of the types of airborne fibers in Silver Bay we undertook a geological survey of their source the Peter Mitchell Pit, and found that there are no primary asbestos minerals at a detectable level.
  • However we identified two non-asbestos types of fibrous minerals in very limited geological locales.
  • We calculate the risk of asbestos-related mesothelioma and lung cancer using a variety of different pessimistic assumptions. (i) that all the non-asbestos fibers are as potent as asbestos fibers used in the EPA-IRIS listing for asbestos; with a calculated risk of asbestos-related cancer for environmental exposure at Silver Bay of 1 excess cancer in 28,500 lifetimes (or 35 excess cancers per 1,000,000 lifetimes) and secondly that taconite associated fibers are as potent as chrysotile the least potent form of asbestos.
  • The calculated risk is less than 0.77 excess cancer case in 1,000,000 lifetimes.
  • Finally, we briefly review the epidemiology studies of grunerite asbestos (amosite) focusing on the exposure conditions associated with increased risk of human mesothelioma.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Iron.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18207296.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Mineral Fibers; 0 / Particulate Matter; 0 / Silicates; 12249-26-2 / taconite; E1UOL152H7 / Iron
  •  go-up   go-down


36. Dainese E, Pozzi B, Milani M, Rossi G, Pezzotta MG, Vertemati G, Tricomi P, Sessa F: Primary pleural epithelioid angiosarcoma. A case report and review of the literature. Pathol Res Pract; 2010 Jun 15;206(6):415-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant vascular tumors are uncommon sarcomas that arise from endothelial cells of small blood vessels and may affect every organ.
  • Even if etiological factors implicated in the development of vascular sarcomas are still unclear, the strongest association with the disease was a history of chronic tuberculous pyothorax, observed only in Japanese patients, while prior radiotherapy and occupational exposure to asbestos have been reported in few Western cases.
  • Immunohistochemistry plays an important role in identifying these rare entities, confirming the endothelial origin of the neoplasm with the expression of at least one of the vascular markers CD31, CD34, or factor VIII-related antigen.
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diabetes Mellitus, Type 2. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Mesothelioma / pathology. Middle Aged. Neoplasm Metastasis / pathology. Radiculopathy / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 20089367.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


37. Adiseshaiah P, Lindner DJ, Kalvakolanu DV, Reddy SP: FRA-1 proto-oncogene induces lung epithelial cell invasion and anchorage-independent growth in vitro, but is insufficient to promote tumor growth in vivo. Cancer Res; 2007 Jul 1;67(13):6204-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We and others have shown a high level of persistent induction of FRA-1 by lung carcinogens, such as cigarette smoke and asbestos, in pulmonary epithelial cells.
  • To examine this aspect, we have stably overexpressed FRA-1 in human type-II-like alveolar malignant cell line (A549) and a nonmalignant bronchial epithelial cell line (BEAS-2B).
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation. Collagen / chemistry. Drug Combinations. Epithelial Cells. Humans. In Vitro Techniques. Laminin / chemistry. Male. Metaplasia / pathology. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Proteoglycans / chemistry

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17616677.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA095020; United States / NCI NIH HHS / CA / CA105005; United States / NCI NIH HHS / CA / CA78282; United States / NIEHS NIH HHS / ES / ES11863; United States / NHLBI NIH HHS / HL / HL66109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Laminin; 0 / Proteoglycans; 0 / Proto-Oncogene Proteins c-fos; 0 / fos-related antigen 1; 119978-18-6 / matrigel; 9007-34-5 / Collagen
  •  go-up   go-down


38. Marier M, Charney W, Rousseau R, Lanthier R, van Raalte J: Exploratory sampling of asbestos in residences near Thetford Mines: the public health threat in Quebec. Int J Occup Environ Health; 2007 Oct-Dec;13(4):386-97
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory sampling of asbestos in residences near Thetford Mines: the public health threat in Quebec.
  • In 2003-2004, the Asbestos Victims Association of Quebec undertook an exploratory sampling of the air and soil in the residential community of asbestos mining towns.
  • The risk of developing asbestos-related cancer following such in-home exposures over 30 years is estimated at 1 in 10,000.
  • [MeSH-major] Air Pollutants / analysis. Asbestos / analysis. Consumer Participation / methods. Environmental Exposure / analysis. Mining. Residence Characteristics

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085052.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Mineral Fibers; 0 / Soil Pollutants; 1332-21-4 / Asbestos
  •  go-up   go-down


39. Berman DW: Comparing milled fiber, Quebec ore, and textile factory dust: has another piece of the asbestos puzzle fallen into place? Crit Rev Toxicol; 2010;40(2):151-88
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing milled fiber, Quebec ore, and textile factory dust: has another piece of the asbestos puzzle fallen into place?
  • Given this performance, the MEM was also applied to address the disparity in lung cancer mortality per unit of exposure observed, respectively, among chrysotile miners/millers in Quebec and SC textile workers.
  • Moreover, phase-contrast microscopy (PCM) structures in Grade 3 dusts are 100% asbestos and counts of PCM-sized structures are identical, whether viewed by PCM or transmission electron microscope (TEM).
  • In contrast, a third of PCM structures in ore dusts are not asbestos and only a third that are counted by PCM are also counted by TEM.
  • Thus, the elutriator may be a valuable tool for reconstructing historical exposures suitable for supporting continued refinements of the risk models being developed to predict asbestos-related cancer risk.
  • [MeSH-major] Air Pollutants, Occupational / analysis. Asbestos / analysis. Dust / analysis. Environmental Exposure / analysis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Crit Rev Toxicol. 2010 Sep;40(8):749-51; author reply 752-7 [20722586.001]
  • (PMID = 20085481.001).
  • [ISSN] 1547-6898
  • [Journal-full-title] Critical reviews in toxicology
  • [ISO-abbreviation] Crit. Rev. Toxicol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Dust; 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Number-of-references] 179
  •  go-up   go-down


40. Greenberg M: Estimating the number of asbestos-related cancer deaths in Great Britain. Ann Occup Hyg; 2006 Jan;50(1):107
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimating the number of asbestos-related cancer deaths in Great Britain.
  • [MeSH-major] Asbestos / toxicity. Lung Neoplasms / mortality. Occupational Diseases / mortality

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Ann Occup Hyg. 2006 Jan;50(1):29-38 [16126764.001]
  • (PMID = 16371419.001).
  • [ISSN] 0003-4878
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement